Novartis Prioritizes Gene Therapy Production With AZ Facility Buy
Executive Summary
A US plant will become the largest of four state-of-the-art sites involved in manufacturing of Novartis unit Avexis' gene therapies headed by Zolgensma, which is widely expected to get the green light from the FDA in May.
You may also be interested in...
Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.